Good news to start 2017, and as predicted, the FDA has approved Allergan’s RHOFADE.
Yes they are going to use uppercase and scream RHOFADE at us everytime we see the product name.
Allergan says that RHOFADE will be available for commercial supply starting May 2017 in the United States.
Once-Daily Treatment Reduces Persistent Facial Erythema (Redness) Associated With Rosacea Through 12 Hours
DUBLIN, Jan. 19, 2017 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today the approval of RHOFADE cream by the U.S. Food and Drug Administration (FDA) for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29.
“The FDA approval of RHOFADE™ exemplifies Allergan’s commitment to continuing to address unmet patient needs through innovation in medical dermatology,” said David Nicholson, Chief R&D Officer of Allergan plc. “We know persistent facial erythema associated with rosacea is a challenge for patients and physicians and having options can help in treating the disease. RHOFADE™ is the first and only alpha1A adrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults. The FDA approval of RHOFADE™ represents a new prescription treatment that can effectively help physicians and their patients manage this condition.”
RHOFADE (oxymetazoline hydrochloride) cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.
- What is Rhofade?
- Waiting for Azultro, Afrin users beware
- Rhofade is Allergan’s Oxymetazoline
- Allergan – Oxymetazoline has no rebound
- Oxymetazoline good for 6 hours and safe for 3 months
- Oxymetazoline: what about rebound redness ?